Brainstorm Cell Therapeutics (STU:GHD) Cyclically Adjusted Book per Share: €11.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
29 GF Score
Price €2.98
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share?

Brainstorm Cell Therapeutics STU:GHD 29 Cyclically Adjusted Book per Share is €11.98 as of Jun. 2026. GuruFocus rates STU:GHD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Brainstorm Cell Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €-0.912. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.98 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Brainstorm Cell Therapeutics's average Cyclically Adjusted Book Growth Rate was -26.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -15.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Brainstorm Cell Therapeutics was 76.00% per year. The lowest was -15.50% per year. And the median was 10.60% per year.

As of today (2026-08-23), Brainstorm Cell Therapeutics's current stock price is €2.979. Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €11.98. Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.25.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Brainstorm Cell Therapeutics was 0.24. The lowest was 0.00. And the median was 0.00.


Brainstorm Cell Therapeutics  (STU:GHD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.979/11.98
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Brainstorm Cell Therapeutics was 0.24. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Related Terms


Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.42 6.50 5.94 8.37 24.83

Brainstorm Cell Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.47 21.18 24.83 13.55 11.98

STU:GHD vs LNAI, BIVI, TOVX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:GHD
29GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brainstorm Cell Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.912/333.9520*333.9520
=-0.912

Current CPI (Jun. 2026) = 333.9520.

Brainstorm Cell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 7.528 241.428 10.413
201612 7.534 241.432 10.421
201703 6.180 243.801 8.465
201706 5.190 244.955 7.076
201709 3.471 246.819 4.696
201712 3.928 246.524 5.321
201803 2.440 249.554 3.265
201806 7.996 251.989 10.597
201809 6.196 252.439 8.197
201812 3.186 251.233 4.235
201903 0.202 254.202 0.265
201906 -2.762 256.143 -3.601
201909 -4.084 256.759 -5.312
201912 -7.120 256.974 -9.253
202003 4.303 258.115 5.567
202006 4.410 257.797 5.713
202009 10.477 260.280 13.443
202012 12.436 260.474 15.944
202103 12.561 264.877 15.837
202106 10.344 271.696 12.714
202109 8.759 274.310 10.663
202112 7.053 278.802 8.448
202203 5.409 287.504 6.283
202206 3.054 296.311 3.442
202209 0.576 296.808 0.648
202212 -1.164 296.797 -1.310
202303 -1.763 301.836 -1.951
202306 -1.313 305.109 -1.437
202309 -0.801 307.789 -0.869
202312 -1.105 306.746 -1.203
202403 -1.119 312.332 -1.196
202406 -0.617 314.175 -0.656
202409 -1.028 315.301 -1.089
202412 -1.207 315.605 -1.277
202503 -0.872 319.799 -0.911
202506 -0.519 322.561 -0.537
202509 -0.594 324.800 -0.611
202512 -0.773 324.054 -0.797
202603 -0.863 330.213 -0.873
202606 -0.912 333.952 -0.912

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €11.98 mean?
Brainstorm Cell Therapeutics (STU:GHD) has a Cyclically Adjusted Book per Share of €11.98 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Cyclically Adjusted Book per Share too high?
Brainstorm Cell Therapeutics' current Cyclically Adjusted Book per Share is €11.98. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Cyclically Adjusted Book per Share compare to LNAI and BIVI?
Brainstorm Cell Therapeutics' Cyclically Adjusted Book per Share of €11.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Cyclically Adjusted Book per Share is €11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current Cyclically Adjusted Book per Share of €11.98. The current Cyclically Adjusted Book per Share is €11.98. Brainstorm Cell Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current Cyclically Adjusted Book per Share is €11.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
29GF Score

Get the complete analysis for STU:GHD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price